Advanced search
Publication Cover
Expert Review of Obstetrics & Gynecology Volume 8, 2013 - Issue 2
Journal homepage
18
Views
1
CrossRef citations to date
0
Altmetric
Review

Early detection of ovarian cancer

Elena Diaz Department of Obstetrics and Gynecology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA
,
Robert E Burky III Department of Obstetrics and Gynecology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA
,
Charles S Hummel Department of Obstetrics and Gynecology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA
&
Robin Farias-Eisner Department of Obstetrics and Gynecology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA. [email protected]
Pages 169-179 | Published online: 10 Jan 2014

References

  • American Cancer Society. Cancer Facts and Figures 2012. American Cancer Society, GA, USA (2012).
  • Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74–108 (2005).
  • Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors. Cancer 97(Suppl. 10), 2631–2642 (2003).
  • Reed N, Millan D, Verheijen R, Castiglione M; ESMO Guidelines Working Group. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v31–v36 (2010).
  • Bridgewater JA, Rustin GJ. Management of non-epithelial ovarian tumours. Oncology 57(2), 89–98 (1999).
  • Barakat RR, Markman M, Randall M. Principles and Practice of Gynecologic Oncology. Lippincott Williams & Wilkins, MD, USA (2009).
  • Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis. Markers 23(5–6), 397–410 (2007).
  • Hulka BS. Cancer screening. Degrees of proof and practical application. Cancer 62(Suppl. 8), 1776–1780 (1988).
  • Schorge JO, Modesitt SC, Coleman RL et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol. Oncol. 119(1), 7–17 (2010).
  • Daly MB, Axilbund JE, Bryant E et al.; National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. J. Natl Compr. Canc. Netw. 4(2), 156–176 (2006).
  • Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 89(10), 2068–2075 (2000).
  • Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291(22), 2705–2712 (2004).
  • Goff BA, Mandel LS, Drescher CW et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 109(2), 221–227 (2007).
  • Andersen MR, Goff BA, Lowe KA et al. Combining a symptoms index with CA125 to improve detection of ovarian cancer. Cancer 113(3), 484–489 (2008).
  • Rossing MA, Wicklund KG, Cushing Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J. Natl Cancer Inst. 102(4), 222–229 (2010).
  • van Nagell JR Jr, Miller RW, DeSimone CP et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet. Gynecol. 118(6), 1212–1221 (2011).
  • van Nagell JR Jr, DePriest PD, Reedy MB et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol. Oncol. 77(3), 350–356 (2000).
  • Merz E, Miric-Tesanic D, Bahlmann F, Weber G, Wellek S. Sonographic size of uterus and ovaries in pre- and postmenopausal women. Ultrasound Obstet. Gynecol. 7(1), 38–42 (1996).
  • Fishman DA, Cohen L, Blank SV et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am. J. Obstet. Gynecol. 192(4), 1214–1221; discussion 1221 (2005).
  • Ueland FR, DePriest PD, Pavlik EJ, Kryscio RJ, van Nagell JR Jr. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecol. Oncol. 91(1), 46–50 (2003).
  • Gollub EL, Westhoff C, Timor-Tritsch IE. Detection of ovaries by transvaginal sonography in postmenopausal women. Ultrasound Obstet. Gynecol. 3(6), 422–425 (1993).
  • Bell RJ, Healy DL, Robertson DM et al. Ovarian status in healthy postmenopausal women: follow-up 12 months after transvaginal ultrasound. Menopause 16(6), 1149–1155 (2009).
  • Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell Proteomics 3(4), 355–366 (2004).
  • O’Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol. 22(6), 348–366 (2001).
  • Rump A, Morikawa Y, Tanaka M et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 279(10), 9190–9198 (2004).
  • Cragun JM. Screening for ovarian cancer. Cancer Control 18(1), 16–21 (2011).
  • Bast RC Jr, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309(15), 883–887 (1983).
  • Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int. J. Cancer 42(5), 677–680 (1988).
  • Skates SJ, Menon U, MacDonald N et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J. Clin. Oncol. 21(Suppl. 10), 206s–210s (2003).
  • Menon U, Skates SJ, Lewis S et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J. Clin. Oncol. 23(31), 7919–7926 (2005).
  • Menon U, Talaat A, Jeyarajah AR et al. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. Br. J. Cancer 80(10), 1644–1647 (1999).
  • Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10(4), 327–340 (2009).
  • Buys SS, Partridge E, Greene MH et al.; PLCO Project Team. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am. J. Obstet. Gynecol. 193(5), 1630–1639 (2005).
  • Partridge E, Kreimer AR, Greenlee RT et al.; PLCO Project Team. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet. Gynecol. 113(4), 775–782 (2009).
  • Buys SS, Partridge E, Black A et al.; PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305(22), 2295–2303 (2011).
  • Shah CA, Lowe KA, Paley P et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers. Cancer Epidemiol. Biomarkers Prev. 18(5), 206–219 (2010).
  • Moore RG, Maclaughlan S. Current clinical use of biomarkers for epithelial ovarian cancer. Curr. Opin. Oncol. 22(5), 492–497 (2010).
  • Huhtinen K, Suvitie P, Hiissa J et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br. J. Cancer 100(8), 1315–1319 (2009).
  • Rosen DG, Wang L, Atkinson JN et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 99(2), 267–277 (2005).
  • Moore RG, Brown AK, Miller MC et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 108(2), 402–408 (2008).
  • Nolen B, Velikokhatnaya L, Marrangoni A et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol. Oncol. 117(3), 440–445 (2010).
  • Husseinzadeh N. Status of tumor markers in epithelial ovarian cancer has there been any progress? A review. Gynecol. Oncol. 120(1), 152–157 (2011).
  • Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl Acad. Sci. USA 93(1), 136–140 (1996).
  • Chang MC, Chen CA, Chen PJ et al. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochem. J. 442(2), 293–302 (2012).
  • Gubbels JA, Belisle J, Onda M et al. Mesothelin–MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer 5(1), 50 (2006).
  • Scholler N, Fu N, Yang Y et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl Acad. Sci. USA 96(20), 11531–11536 (1999).
  • McIntosh MW, Drescher C, Karlan B et al. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol. 95(1), 9–15 (2004).
  • Badgwell D, Lu Z, Cole L et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG β core fragment. Gynecol. Oncol. 106(3), 490–497 (2007).
  • Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287(13), 1671–1679 (2002).
  • Nakae M, Iwamoto I, Fujino T et al. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J. Obstet. Gynaecol. Res. 32(3), 309–314 (2006).
  • Schorge JO, Drake RD, Lee H et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin. Cancer Res. 10(10), 3474–3478 (2004).
  • Visintin I, Feng Z, Longton G et al. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 14(4), 1065–1072 (2008).
  • Lennartsson AK, Jonsdottir IH. Prolactin in response to acute psychosocial stress in healthy men and women. Psychoneuroendocrinology 36(10), 1530–1539 (2011).
  • Nosov V, Su F, Amneus M et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am. J. Obstet. Gynecol. 200(6), 639.e1–639.e5 (2009).
  • Amonkar SD, Bertenshaw GP, Chen TH et al. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS ONE 4(2), e4599 (2009).
  • Anderson GL, McIntosh M, Wu L et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case–control study. J. Natl Cancer Inst. 102(1), 26–38 (2010).
  • Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 112(1), 40–46 (2009).
  • Moore RG, Jabre-Raughley M, Brown AK et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am. J. Obstet. Gynecol. 203(3), 228. e1–228.e6 (2010).
  • Yurkovetsky Z, Skates S, Lomakin A et al. Development of a multimarker assay for early detection of ovarian cancer. J. Clin. Oncol. 28(13), 2159–2166 (2010).
  • Muller CY. Doctor, should I get this new ovarian cancer test – OVA1? Obstet. Gynecol. 116(2), 246–247 (2010).
  • Ueland FR, Desimone CP, Seamon LG et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet. Gynecol. 117(6), 1289–1297 (2011).
  • Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572–577 (2002).
  • Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl Cancer Inst. 97(4), 315–319 (2005).
  • Leiserowitz GS, Lebrilla C, Miyamoto S et al. Glycomics analysis of serum: a potential new biomarker for ovarian cancer? Int. J. Gynecol. Cancer 18(3), 470–475 (2008).
  • Denkert C, Budczies J, Kind T et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 66(22), 10795–10804 (2006).
  • Slupsky CM, Steed H, Wells TH et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin. Cancer Res. 16(23), 5835–5841 (2010).
  • Liu Y, Chen Y, Momin A et al. Elevation of sulfatides in ovarian cancer: an integrated transcriptomic and lipidomic analysis including tissue-imaging mass spectrometry. Mol. Cancer. 9, 186 (2010).
  • Zhang L, Volinia S, Bonome T et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc. Natl Acad. Sci. USA 105(19), 7004–7009 (2008).
  • Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 67(18), 8699–8707 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.